Abstract
Among genito-urinary tumors, gemcitabine is indicated only for the treatment of locally advanced and metastatic urothelial cancer. The combination of gemcitabine and cisplatin is a new standard in this disease. Gemcitabine shows activity in refractory germ cell tumors. In salvage treatment its role is ongoing evaluation. The combination of gemcitabine and 5-fuoruracile has modest activity in renal cell carcinoma. Pemetrexed is not indicating in genitor-urinary tumors, further evaluation in urothelial cancer is warranted.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
